Keyphrases
Conditioning Regimen
100%
Hemoglobinopathies
100%
Single-center Experience
100%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
100%
Busulfan
100%
Thalassemia
83%
Graft-versus-host Disease (GvHD)
66%
Venous Disease
50%
Sickle Cell Anemia
33%
Cumulative Incidence
33%
Hematopoietic Stem Cell Transplantation
33%
Stem Cells
16%
Israel
16%
Low Incidence
16%
In(III)
16%
Peripheral Blood
16%
Pediatric Patients
16%
Medical Center
16%
Transplantation
16%
Bone Marrow
16%
β-Thalassemia (β-thal)
16%
Unrelated Donor
16%
Engraftment
16%
Cord Blood
16%
Haifa
16%
Standard of Care
16%
Overall Survival
16%
Pretransplant
16%
Area under the Curve
16%
Pharmacokinetic Analysis
16%
5-year Survival
16%
Dose Adjustment
16%
Free Survival
16%
Myeloablative Conditioning
16%
Day Range
16%
Donor chimerism
16%
Platelet Transfusion
16%
Neutrophil Engraftment
16%
Second Transplant
16%
Transfusion Independence
16%
Treatment-related Morbidity
16%
Medicine and Dentistry
Hemoglobinopathy
100%
Transplantation
100%
Allogeneic Stem Cell Transplantation
100%
Busulfan
100%
Thalassemia
71%
Vein Occlusion
42%
Conditioning
28%
Sickle-Cell Disease
28%
Cumulative Incidence
28%
Engraftment
28%
Overall Survival
28%
Hematopoietic Stem Cell Transplantation
28%
Chronic Graft Versus Host Disease
28%
Pediatrics Patient
14%
Stem Cell
14%
Bone Marrow Transplantation
14%
Cord Blood
14%
Neutrophil
14%
Pharmacokinetics
14%
Chimera
14%
Thalassemia Major
14%
Thrombocyte Transfusion
14%
Graft Versus Host Reaction
14%
Acute Graft Versus Host Disease
14%
Myeloablative Conditioning
14%
Nursing and Health Professions
Transplantation
100%
Busulfan
100%
Allogeneic Stem Cell Transplantation
100%
Hemoglobinopathy
100%
Thalassemia
71%
Vein Occlusion
42%
Overall Survival
28%
Hematopoietic Stem Cell Transplantation
28%
Engraftment
28%
Chronic Graft Versus Host Disease
28%
Sickle Cell Anemia
28%
Pediatrics Patient
14%
Health Care Quality
14%
Area under the Curve
14%
Graft Versus Host Reaction
14%
Bone Marrow Transplantation
14%
Thalassemia Major
14%
Thrombocyte Transfusion
14%
Acute Graft Versus Host Disease
14%
Myeloablative Conditioning
14%
Pharmacology, Toxicology and Pharmaceutical Science
Hemoglobinopathy
100%
Busulfan
100%
Thalassemia
83%
Vein Occlusion
50%
Sickle Cell Anemia
33%
Overall Survival
33%
Chronic Graft Versus Host Disease
33%
Thalassemia Major
16%
Pharmacokinetics
16%
Graft Versus Host Reaction
16%
Acute Graft Versus Host Disease
16%